Posaconazole therapeutic drug monitoring (TDM) is widely utilized to assess therapeutic efficacy and safety; however, clinical effects of very high serum concentrations are unknown. A retrospective review of 90 patients receiving posaconazole for treatment or prophylaxis of invasive fungal infections with serum concentrations ≥3000 ng/mL from 1/1/2019 to 4/30/2021 evaluated the incidence and type of adverse drug reactions (ADRs). Symptomatic ADRs were very common in patients with posaconazole concentrations of ≥5000 ng/mL and 3000-4999 ng/mL (80% vs. 58.8%; P = 0.31). Posaconazole TDM should be performed for both treatment and prophylaxis indications and dose decrease for serum concentrations >3000 ng/mL should be considered.
CITATION STYLE
Jensen, K., Saleh, O. A., Chesdachai, S., Jannetto, P. J., Mara, K. C., Yetmar, Z. A., & Rivera, C. G. (2023). Association of adverse effects with high serum posaconazole concentrations. Medical Mycology, 61(8). https://doi.org/10.1093/mmy/myad079
Mendeley helps you to discover research relevant for your work.